Market - iData Insights - ReDiscovering Data | Research Reports, News, Events, Research on Demand

Sectors


Price








Published







Research Reports Titles

  • Multiple Myeloma - Current and Future Players

    Multiple Myeloma - Current and Future Players Summary GlobalData has released its pharma report,  Multiple Myeloma - Current and Future Players . The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Myeloma Market. The report identifies and analyses the key companies shaping and driving the global Multiple Myeloma market. The report provides insight into the competitive Multiple Myeloma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for Multiple Myeloma - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Multiple Myeloma sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving Multiple Myeloma market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What s the next big thing in the global Multiple Myeloma market landscape? Identify, understand and capitalize

    • Release Date: November 01, 2015
    • Price: USD 2995
    • Format: PDF

  • Peripheral Artery Disease - US Drug Forecast and Market Analysis to 2024

    Peripheral Artery Disease - US Drug Forecast and Market Analysis to 2024 Summary In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co. s Zontivity (vorapaxar), AstraZeneca s Brilinta (ticagrelor), and Bayer and Janssen s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape. The total US sales for the PAD therapeutics market in the 2014 base year was approximately $191.4m. The statin share can chiefly be attributed to sales volume, as most statins, with the exception of Crestor, are available as inexpensive generics. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product PADcription, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting the US PAD market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for PAD. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in US.

    • Release Date: October 01, 2015
    • Price: USD 4995
    • Format: PDF

  • Peripheral Artery Disease - Japan Drug Forecast and Market Analysis to 2024

    Peripheral Artery Disease - Japan Drug Forecast and Market Analysis to 2024 Summary In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co. s Zontivity (vorapaxar), AstraZeneca s Brilinta (ticagrelor), and Bayer and Janssen s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape. In the 2014 base year, GlobalData determined that the PAD therapeutics market in Japan was worth $59.5m. The remainder of the 2014 PAD market in Japan came from prostaglandins, which are used to ameliorate the symptoms of PAD, and cilostazol, which is used as an antiplatelet agent in this market. In total, these drugs generated approximately $31.4m in 2014. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Japan including product PADcription, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Japan from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting Japan PAD market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for PAD. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in Japan.

    • Release Date: October 01, 2015
    • Price: USD 4995
    • Format: PDF

  • Peripheral Artery Disease - China Drug Forecast and Market Analysis to 2024

    Peripheral Artery Disease - China Drug Forecast and Market Analysis to 2024 Summary In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co. s Zontivity (vorapaxar), AstraZeneca s Brilinta (ticagrelor), and Bayer and Janssen s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape. In 2014, the PAD therapeutics market in China was worth approximately $93.7m. Generic anticoagulant drugs, primarily warfarin, will suffer a negative CAGR of approximately 10.15% as Xarelto and generic rivaroxaban begin to encroach on warfarin s stake in the PAD market. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in China including product PADcription, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in China from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting China PAD market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for PAD. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in China.

    • Release Date: October 01, 2015
    • Price: USD 4995
    • Format: PDF

  • Peripheral Artery Disease - 5EU China Drug Forecast and Market Analysis to 2024

    Peripheral Artery Disease - 5EU China Drug Forecast and Market Analysis to 2024 Summary In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co. s Zontivity (vorapaxar), AstraZeneca s Brilinta (ticagrelor), and Bayer and Janssen s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape. Total 5EU sales for the PAD therapeutics market in 2014 was approximately $198.8m. By 2024, sales of drugs that are used to relieve the symptoms of PAD will decline quite dramatically. This group of medicines will only contribute approximately 5% to total 5EU PAD sales by the end of the forecast period. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product PADcription, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting 5EU PAD market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for PAD. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in 5EU.

    • Release Date: October 01, 2015
    • Price: USD 6995
    • Format: PDF

  • Peripheral Artery Disease - Current and Future Players

    Peripheral Artery Disease - Current and Future Players Summary GlobalData has released its pharma report,  Peripheral Artery Disease - Current and Future Players . The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Peripheral Artery Disease Market. The report identifies and analyses the key companies shaping and driving the global Peripheral Artery Disease market. The report provides insight into the competitive Peripheral Artery Disease landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for Peripheral Artery Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Peripheral Artery Disease sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving Peripheral Artery Disease market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What s the next big thing in the global Peripheral Artery Disease market landscape? Identify, understand and capitalize

    • Release Date: October 01, 2015
    • Price: USD 2995
    • Format: PDF

  • Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023

    Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline s (GSK s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience. Over the forecast period, the major driver of growth in the US HIV therapeutics market will be the launch of new drugs that offer improvements in terms of the pill burden, tolerability, and efficacy. Novel STRs will have the strongest positive impact on the market, and the drugs within this class of ART regimens include ViiV s recently launched INI-based STR, Triumeq, which was the first regimen to show superiority over Atripla. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Human Immunodeficiency Virus (HIV) market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV). - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the US

    • Release Date: September 09, 2015
    • Price: USD 4995
    • Format: PDF

  • Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023

    Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline s (GSK s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience. The Japanese HIV market also differs from that of the US and the 5EU in that the uptake of STRs has been less pronounced. For example, Atripla, which has become a leading HIV drug across the 6MM, is not currently licensed in Japan. Gilead s Stribild, an INI-based STR that was approved by the FDA in August 2012, became the first STR to be licensed in Japan, in early 2013 (Japan Tobacco, press release, March 25, 2013). *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the Japan from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the Japan Human Immunodeficiency Virus (HIV) market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV). - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the Japan.

    • Release Date: September 09, 2015
    • Price: USD 4995
    • Format: PDF

  • Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023

    Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline s (GSK s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience. Gilead s first-in-class, NNRTI-based STR, Atripla, performed well, with its 2013 sales in the 5EU topping $830m (26% market share), despite competing in a highly fragmented market that featured over 18 different drugs spanning all classes of antiretrovirals, many of which, particularly NRTIs and NNRTIs, had already lost patent protection. Since Atripla s successful 5EU launch in 2007, companies have strived to develop STRs for this market, and these novel products are anticipated to heavily influence the future market dynamics. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the 5EU from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Human Immunodeficiency Virus (HIV) market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV). - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the 5EU

    • Release Date: September 09, 2015
    • Price: USD 6995
    • Format: PDF

  • Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023

    Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline s (GSK s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience. The HIV therapeutics market in Brazil was valued at approximately $337m in 2013. In contrast to the 7MM, where branded therapies dominate the treatment landscape, HIV drug sales in Brazil are primarily attributable to generics. The branded STRs and FDCs that dominated the 7MM in 2013, such as ViiV s Epzicom and Gilead s HIV franchise (Atripla, Stribild, Complera, and Truvada), are still unavailable in Brazil due to their high price tags, with the government instead opting for the use of cheaper generics to address the growing demand for ART. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the Brazil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the Brazil from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the Brazil Human Immunodeficiency Virus (HIV) market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV). - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the Brazil.

    • Release Date: September 09, 2015
    • Price: USD 4995
    • Format: PDF


Create Account



Log In Your Account